CA-BE-MY-EYES
14.3.2023 18:04:39 CET | Business Wire | Press release
Be My Eyes, the mobile app that allows anyone to assist visually impaired people through live video calls, today announced Virtual Volunteer™, the first-ever digital visual assistant powered by OpenAI’s new GPT-4 language model.
The new tool from Be My Eyes integrates OpenAI’s latest generative AI technology, with the goal of providing an unprecedented level of accessibility and power to the 253 million people who are blind or have low vision globally.
“We are entering the next wave of innovation for accessibility technology powered by AI. This new Be My Eyes feature will be transformative in providing people who are blind or have low vision with powerful tools to better navigate physical environments, address everyday needs, and gain more independence,” said Mike Buckley, CEO of Be My Eyes. “We are thrilled to work with OpenAI to further our mission of improving accessibility for the 253 million people who are blind or have low-vision, with safe and accessible applications of generative AI.”
The Virtual Volunteer feature will be integrated into the existing app and contains a dynamic new image-to-text generator powered by GPT-4. Users can send images via the app to an AI-powered Virtual Volunteer, which will answer any question about that image and provide instantaneous, conversational visual assistance for a wide variety of tasks.
What sets the Virtual Volunteer tool apart from other image-to-text technology available today is the context it provides, with highly nuanced explanations and conversational abilities not yet seen in the digital assistant field. For example, if a user sends a picture of the inside of their refrigerator, the Virtual Volunteer will not only be able to correctly identify the items within, but also extrapolate and analyze what can be prepared with those ingredients. The tool can also then offer a number of recipes for those ingredients and send a step-by-step guide to prepare them.
This new feature promises to not only better support the blind and low-vision community through the Be My Eyes app, but it will also offer a way for businesses to better serve their customers by prioritizing accessibility. Be My Eyes plans to begin beta testing this with corporate customers in the coming weeks, and to make it broadly available later this year as part of the company’s Accessible CX™ offering.
Since its founding in 2015, Be My Eyes has worked to connect its 6.3 million volunteers to users to assist them with everyday tasks, and the company’s mission is to make the world more accessible for people who are blind or have low vision.
In the near future, Be My Eyes plans to apply this technology to provide people with powerful tools and capabilities to enrich their virtual assistant experience in complex ways – for example, navigating a train system in an unfamiliar place, traveling in a foreign country where translation support is needed, browsing websites and social media platforms, online shopping, and a host of other scenarios to be discovered in testing.
People who are blind or have low vision can register for the wait list in the iOS app. Just like the existing volunteer service, this tool is free for all blind and low-vision community members using the Be My Eyes app.
About Be My Eyes
Based in Denmark and launched in 2015, Be My Eyes is a global community that connects people who are blind or have low vision with sighted volunteers or company representatives. On the app, volunteers assist blind and low-vision users through a live video connection and work together to tackle challenges and handle a wide range of tasks. With the Specialized Help feature, blind and low-vision users can connect with company representatives for accessible customer support. The app harnesses the power of generosity, technology, and human connection so that people who are blind or have low vision can lead more independent lives. Be My Eyes is accessible in more than 150 countries worldwide and in over 180 languages. The app is free and available for both iOS and Android. Learn more at bemyeyes.com and join us on LinkedIn, Twitter, Facebook, Instagram, and TikTok.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
